Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 124, Issue 7
August 14 2014
Issue Cover

Table of Contents

INSIDE BLOOD COMMENTARIES

INSIDE BLOOD COMMENTARY
Novel insights related to CF neutrophils
Silvia M. Uriarte
View Articletitled, Novel insights related to CF neutrophils
INSIDE BLOOD COMMENTARY
Oral therapy for multiple myeloma: ixazomib arriving soon
Clinical Trials & Observations
Philippe Moreau
View Articletitled, Oral therapy for multiple myeloma: ixazomib arriving soon
INSIDE BLOOD COMMENTARY
First do no harm: infectious deaths in pediatric ALL
Clinical Trials & Observations
Karen R. Rabin
View Articletitled, First do no harm: infectious deaths in pediatric ALL
INSIDE BLOOD COMMENTARY
Old and new news in CLL: “It’s the pathway, stupid!”
Alexander Egle
View Articletitled, Old and new news in CLL: “It’s the pathway, stupid!”
INSIDE BLOOD COMMENTARY
A common progenitor cell in LCH and ECD
Gayane Badalian-Very
View Articletitled, A common progenitor cell in LCH and ECD
INSIDE BLOOD COMMENTARY
Is JAK2V617F finally off the hook?
Ingeborg Hers,Alastair W. Poole
View Articletitled, Is JAK2<sup>V617F</sup> finally off the hook?
INSIDE BLOOD COMMENTARY
A step forward back to (induced) fetal
Nancy S. Green
View Articletitled, A step forward back to (induced) fetal
INSIDE BLOOD COMMENTARY
Less (bacterial diversity) is more (deaths)
John E. Levine
View Articletitled, Less (bacterial diversity) is more (deaths)

BLOOD WORK

Nodular sclerosis Hodgkin lymphoma with classic Reed-Sternberg cells
Selina Jing Li,Suzanne Maria Vercauteren
View Articletitled, Nodular sclerosis Hodgkin lymphoma with classic Reed-Sternberg cells
Auer rods in dysplastic granulocyte
Anila Rashid
View Articletitled, Auer rods in dysplastic granulocyte

PLENARY PAPER

A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy
Kerstin Pohl,Elaine Hayes,Joanne Keenan,Michael Henry,Paula Meleady,Kevin Molloy,Bakr Jundi,David A. Bergin,Cormac McCarthy,Oliver J. McElvaney,Michelle M. White,Martin Clynes,Emer P. Reeves,Noel G. McElvaney
View Articletitled, A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy
Supplemental data

PERSPECTIVES

Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy
Giorgia Simonetti,Maria Teresa Sabrina Bertilaccio,Paolo Ghia,Ulf Klein
View Articletitled, Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy
Supplemental data

REVIEW ARTICLE

Evolving use of new oral anticoagulants for treatment of venous thromboembolism
Clinical Trials & Observations
Calvin H. Yeh,Peter L. Gross,Jeffrey I. Weitz
View Articletitled, Evolving use of new oral anticoagulants for treatment of venous thromboembolism
Extracellular nucleotide and nucleoside signaling in vascular and blood disease
Marco Idzko,Davide Ferrari,Ann-Kathrin Riegel,Holger K. Eltzschig
View Articletitled, Extracellular nucleotide and nucleoside signaling in vascular and blood disease

CLINICAL TRIALS AND OBSERVATIONS

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients
Clinical Trials & Observations
Paul G. Richardson,Rachid Baz,Michael Wang,Andrzej J. Jakubowiak,Jacob P. Laubach,R. Donald Harvey,Moshe Talpaz,Deborah Berg,Guohui Liu,Jiang Yu,Neeraj Gupta,Alessandra Di Bacco,Ai-Min Hui,Sagar Lonial
View Articletitled, Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients
Supplemental data
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma
Clinical Trials & Observations
Shaji K. Kumar,William I. Bensinger,Todd M. Zimmerman,Craig B. Reeder,James R. Berenson,Deborah Berg,Ai-Min Hui,Neeraj Gupta,Alessandra Di Bacco,Jiang Yu,Yaping Shou,Ruben Niesvizky
View Articletitled, Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma
Supplemental data
Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003
Clinical Trials & Observations
David O’Connor,Jessica Bate,Rachel Wade,Rachel Clack,Sunita Dhir,Rachael Hough,Ajay Vora,Nick Goulden,Sujith Samarasinghe
View Articletitled, Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003
Supplemental data
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
Clinical Trials & Observations
Elisa Rumi,Daniela Pietra,Cristiana Pascutto,Paola Guglielmelli,Alejandra Martínez-Trillos,Ilaria Casetti,Dolors Colomer,Lisa Pieri,Marta Pratcorona,Giada Rotunno,Emanuela Sant’Antonio,Marta Bellini,Chiara Cavalloni,Carmela Mannarelli,Chiara Milanesi,Emanuela Boveri,Virginia Ferretti,Cesare Astori,Vittorio Rosti,Francisco Cervantes,Giovanni Barosi,Alessandro M. Vannucchi,Mario Cazzola,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators
View Articletitled, Clinical effect of driver mutations of <em>JAK2</em>, <em>CALR</em>, or <em>MPL</em> in primary myelofibrosis

GENE THERAPY

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells
Sonia Guedan,Xi Chen,Aviv Madar,Carmine Carpenito,Shannon E. McGettigan,Matthew J. Frigault,Jihyun Lee,Avery D. Posey, Jr,John Scholler,Nathalie Scholler,Richard Bonneau,Carl H. June
View Articletitled, ICOS-based chimeric antigen receptors program bipolar T<sub>H</sub>17/T<sub>H</sub>1 cells
Supplemental data

IMMUNOBIOLOGY

Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15
Masaru Imamura,David Shook,Takahiro Kamiya,Noriko Shimasaki,Sally M. H. Chai,Elaine Coustan-Smith,Chihaya Imai,Dario Campana
View Articletitled, Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15
Supplemental data

LYMPHOID NEOPLASIA

Somatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL
Lili Wang,Alex K. Shalek,Mike Lawrence,Ruihua Ding,Jellert T. Gaublomme,Nathalie Pochet,Petar Stojanov,Carrie Sougnez,Sachet A. Shukla,Kristen E. Stevenson,Wandi Zhang,Jessica Wong,Quinlan L. Sievers,Bryan T. MacDonald,Alexander R. Vartanov,Natalie R. Goldstein,Donna Neuberg,Xi He,Eric Lander,Nir Hacohen,Aviv Regev,Gad Getz,Jennifer R. Brown,Hongkun Park,Catherine J. Wu
View Articletitled, Somatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL
Supplemental data
Plasmacytomagenesis in Eμ-v-abl transgenic mice is accelerated when apoptosis is restrained
Cassandra J. Vandenberg,Paul Waring,Andreas Strasser,Suzanne Cory
View Articletitled, Plasmacytomagenesis in Eμ-v-<em>abl</em> transgenic mice is accelerated when apoptosis is restrained
Supplemental data

MYELOID NEOPLASIA

Characterization of acute myeloid leukemia based on levels of global hydroxymethylation
Leonie I. Kroeze,Mariam G. Aslanyan,Arno van Rooij,Theresia N. Koorenhof-Scheele,Marion Massop,Thomas Carell,Jan B. Boezeman,Jean-Pierre Marie,Constantijn J. M. Halkes,Theo de Witte,Gerwin Huls,Stefan Suciu,Ron A. Wevers,Bert A. van der Reijden,Joop H. Jansen,on behalf of the EORTC Leukemia Group and GIMEMA,on behalf of the EORTC Leukemia Group and GIMEMA,on behalf of the EORTC Leukemia Group and GIMEMA,on behalf of the EORTC Leukemia Group and GIMEMA,on behalf of the EORTC Leukemia Group and GIMEMA,on behalf of the EORTC Leukemia Group and GIMEMA,on behalf of the EORTC Leukemia Group and GIMEMA,on behalf of the EORTC Leukemia Group and GIMEMA,on behalf of the EORTC Leukemia Group and GIMEMA,on behalf of the EORTC Leukemia Group and GIMEMA,on behalf of the EORTC Leukemia Group and GIMEMA,on behalf of the EORTC Leukemia Group and GIMEMA,on behalf of the EORTC Leukemia Group and GIMEMA,on behalf of the EORTC Leukemia Group and GIMEMA,on behalf of the EORTC Leukemia Group and GIMEMA
View Articletitled, Characterization of acute myeloid leukemia based on levels of global hydroxymethylation
Supplemental data
Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation
Baptiste Hervier,Julien Haroche,Laurent Arnaud,Frédéric Charlotte,Jean Donadieu,Antoine Néel,François Lifermann,Carles Villabona,Bruno Graffin,Olivier Hermine,Aude Rigolet,Camille Roubille,Eric Hachulla,Thierry Carmoi,Maud Bézier,Véronique Meignin,Marie Conrad,Laurence Marie,Elise Kostrzewa,Jean-Marie Michot,Stéphane Barete,Valerie Taly,Karine Cury,Jean-François Emile,Zahir Amoura,on behalf of the French Histiocytoses Study Group,on behalf of the French Histiocytoses Study Group,on behalf of the French Histiocytoses Study Group,on behalf of the French Histiocytoses Study Group,on behalf of the French Histiocytoses Study Group,on behalf of the French Histiocytoses Study Group,on behalf of the French Histiocytoses Study Group,on behalf of the French Histiocytoses Study Group,on behalf of the French Histiocytoses Study Group,on behalf of the French Histiocytoses Study Group,on behalf of the French Histiocytoses Study Group,on behalf of the French Histiocytoses Study Group,on behalf of the French Histiocytoses Study Group,on behalf of the French Histiocytoses Study Group,on behalf of the French Histiocytoses Study Group,on behalf of the French Histiocytoses Study Group,on behalf of the French Histiocytoses Study Group,on behalf of the French Histiocytoses Study Group,on behalf of the French Histiocytoses Study Group,on behalf of the French Histiocytoses Study Group,on behalf of the French Histiocytoses Study Group,on behalf of the French Histiocytoses Study Group,on behalf of the French Histiocytoses Study Group,on behalf of the French Histiocytoses Study Group,on behalf of the French Histiocytoses Study Group
View Articletitled, Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the <em>BRAF</em><sup>V600E</sup> mutation
Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells
Yin Wang,Yan Liu,Fei Tang,Kelsie M. Bernot,Reuven Schore,Guido Marcucci,Michael A. Caligiuri,Pan Zheng,Yang Liu
View Articletitled, Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells
Supplemental data

PLATELETS AND THROMBOPOIESIS

Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm
Lamia Lamrani,Catherine Lacout,Véronique Ollivier,Cécile V. Denis,Elizabeth Gardiner,Benoit Ho Tin Noe,William Vainchenker,Jean-Luc Villeval,Martine Jandrot-Perrus
View Articletitled, Hemostatic disorders in a JAK2<sup>V617F</sup>-driven mouse model of myeloproliferative neoplasm
Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

Hydroxyurea-inducible SAR1 gene acts through the Giα/JNK/Jun pathway to regulate γ-globin expression
Jianqiong Zhu,Kyung Chin,Wulin Aerbajinai,Chutima Kumkhaek,Hongzhen Li,Griffin P. Rodgers
View Articletitled, Hydroxyurea-inducible <em>SAR1</em> gene acts through the Giα/JNK/Jun pathway to regulate γ-globin expression
Supplemental data

THROMBOSIS AND HEMOSTASIS

The endothelial protein C receptor enhances hemostasis of FVIIa administration in hemophilic mice in vivo
Giulia Pavani,Lacramioara Ivanciu,Armida Faella,Oscar A. Marcos-Contreras,Paris Margaritis
View Articletitled, The endothelial protein C receptor enhances hemostasis of FVIIa administration in hemophilic mice in vivo
Supplemental data
Postthrombotic syndrome following upper extremity deep vein thrombosis in children
Maria L. Avila,Lucy Duan,Amanda Cipolla,Ashley Kim,Walter H. A. Kahr,Suzan Williams,Leonardo R. Brandão
View Articletitled, Postthrombotic syndrome following upper extremity deep vein thrombosis in children

TRANSPLANTATION

The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation
Ying Taur,Robert R. Jenq,Miguel-Angel Perales,Eric R. Littmann,Sejal Morjaria,Lilan Ling,Daniel No,Asia Gobourne,Agnes Viale,Parastoo B. Dahi,Doris M. Ponce,Juliet N. Barker,Sergio Giralt,Marcel van den Brink,Eric G. Pamer
View Articletitled, The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation
Supplemental data
MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis
Damiano Rondelli,Judith D. Goldberg,Luis Isola,Leah S. Price,Tsiporah B. Shore,Michael Boyer,Andrea Bacigalupo,Alessandro Rambaldi,Marco Scarano,Rebecca B. Klisovic,Vikas Gupta,Bjorn Andreasson,John Mascarenhas,Meir Wetzler,Alessandro M. Vannucchi,Josef T. Prchal,Vesna Najfeld,Attilio Orazi,Rona S. Weinberg,Crystal Miller,Giovanni Barosi,Lewis R. Silverman,Giuseppe Prosperini,Roberto Marchioli,Ronald Hoffman
View Articletitled, MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis

CORRESPONDENCE

Blood collection methods affect cellular protein integrity: implications for clinical trial biomarkers and ZAP-70 in CLL
Lisa S. Chen,Michael J. Keating,Varsha Gandhi
View Articletitled, Blood collection methods affect cellular protein integrity: implications for clinical trial biomarkers and ZAP-70 in CLL
Activation of TRKB receptor in murine hematopoietic stem/progenitor cells induced mastocytosis
Min Yang,Kezhi Huang,Guntram Büsche,Arnold Ganser,Zhixiong Li
View Articletitled, Activation of TRKB receptor in murine hematopoietic stem/progenitor cells induced mastocytosis
Supplemental data
Engraftment of donor cells with germ-line integration of HHV6 mimics HHV6 reactivation following cord blood/haplo transplantation
Enkhtsetseg Purev,Thomas Winkler,Robert L. Danner,Gary A. Fahle,Linda Cook,Danielle M. Zerr,Keith R. Jerome,Richard W. Childs
View Articletitled, Engraftment of donor cells with germ-line integration of HHV6 mimics HHV6 reactivation following cord blood/haplo transplantation

ERRATA

Wolyniec K, Shortt J, de Stanchina E, et al. E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis. Blood. 2012;120(4):822-832.
View Articletitled, Wolyniec K, Shortt J, de Stanchina E, et al. E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis. <em>Blood.</em> 2012;120(4):<span class="related-article">822-832</span>.
Eriguchi Y, Takashima S, Oka H, et al. Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting Paneth cell production of α-defensins. Blood. 2012;120(1):223-231.
View Articletitled, Eriguchi Y, Takashima S, Oka H, et al. Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting Paneth cell production of α-defensins. <em>Blood</em>. 2012;120(1):<span class="related-article">223-231</span>.
Rothe A, Sasse S, Goergen H, et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. Blood. 2012;120(7):1470-1472.
View Articletitled, Rothe A, Sasse S, Goergen H, et al. Brentuximab vedotin for relapsed or refractory CD30<sup>+</sup> hematologic malignancies: the German Hodgkin Study Group experience. <em>Blood</em>. 2012;120(7):<span class="related-article">1470-1472</span>.
San-Miguel J, Bladé J, Shpilberg O, et al. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti–IL-6) in multiple myeloma. Blood. 2014;123(26):4136-4142.
View Articletitled, San-Miguel J, Bladé J, Shpilberg O, et al. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti–IL-6) in multiple myeloma. <em>Blood</em>. 2014;123(26):<span class="related-article">4136-4142</span>.
All Issues

Advertisement intended for health care professionals

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma
Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation
Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation
Prothrombotic Antibodies Targeting the Spike Protein's Receptor-Binding Domain in Severe COVID-19
The Contribution of the Monocyte‐Macrophage Lineage to Immunotherapy Outcomes

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals